Revolution Medicines, Inc. is a clinical-stage precision oncology company developing targeted therapies for RAS-addicted cancers. The company utilizes a proprietary tri-complex technology platform to create small molecule inhibitors that bind directly to the active, GTP-bound form of RAS, known as RAS(ON). Its pipeline includes multi-selective inhibitors like daraxonrasib (RMC-6236) and mutant-selective inhibitors such as zoldonrasib (RMC-9805) for G12D, elironrasib (RMC-6291) for G12C, and RMC-5127 for G12V. These compounds are designed for use as monotherapy or in combination with standard of care treatments and other RAS(ON) inhibitors. The company focuses on treating cancers driven by RAS mutations, including non-small cell lung cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. Clinical trials are ongoing globally, with several compounds receiving Breakthrough Therapy Designation from the U.S. Food and Drug Administration.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage revmed.com
Sector Healthcare IR page ir.revmed.com
Tags
precision oncology, ras inhibitors, small molecule drugs, pancreatic cancer, non-small cell lung cancer, colorectal cancer, targeted therapy, clinical-stage, daraxonrasib, RMC-6236, zoldonrasib, RMC-9805, elironrasib, RMC-6291, RMC-5127, RMC-0708, RMC-8839, tri-complex technology platform
Press page —

Metrics

Valuation  
Market cap $ 36.566B
Market cap (USD) $ 36.566B
P/E -18.48
PEG —
P/BV 15.23
P/S —
P/OCF -25.55
P/FCF -25.38
Dividend yield —
Turnover / mcap —
Returns  
ROE -58.1%
ROI -81.4%
ROIC -63.8%
Profit margin —
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 43
Quality score -75.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Revenue 0 0 11.58M 35.38M 29.39M 42.983M 50.041M
Net profit -1.131B -600.093M -436.367M -248.705M -187.091M -108.159M -47.664M
Free cash flow -913.731M -567.744M -358.301M -235.217M -153.708M -102.997M -52.205M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Share price 79.65 43.74 28.68 23.82 25.17 39.59 —
Price performance 12m 0.82 0.53 0.2 -0.05 -0.36 — —

Filed figures

Figure Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — 172,000 32.7M 66.6M 64.2M 87.9M 136M 159M
Cash and deposits (USD) 69.6M 16.7M 104M 108M 161M 696M 543M 384M
Intangible assets (USD) — 62M 60.9M 59.9M 58.8M 57.7M 56.7M 55.8M
Right-of-use assets (USD) — — 27.4M 59.7M 55.1M 77.1M 118M 132M
Cash flow detail
Operating cash flow (USD) 1.21M -49.6M -100M -147M -224M -351M -557M -898M
Purchases of property, plant and equipment (USD) -1.5M -2.59M -2.93M -6.53M -10.8M -7.73M -10.3M -16M
Change in receivables (cash effect) (USD) — -1.43M 2.34M 464,000 1.26M 3.42M 1.25M 0.00
Change in payables (cash effect) (USD) 109,000 5.26M 305,000 2.24M 7.29M 32.5M -6.47M 9.54M
Dividends paid (cash effect) (USD) — — 0.00 — — — — —
Share-based compensation (USD) 855,000 3.16M 8.89M 20.7M 31.2M 61.8M 79.2M 118M
Operating cash flow before change in receivables (USD) — -48.2M -102M -148M -226M -354M -559M -898M
Free cash flow (OCF - PPE - intangibles) (USD) -286,000 -52.2M -103M -154M -235M -358M -568M -914M
Income detail
Research and development expense (USD) 51.1M 91.8M 132M 187M 253M 423M 592M 987M
↳ 5y CAGR +52.6% +45.2% +49.5%
Total comprehensive income (USD) -41.8M -47.6M -108M -188M -250M -434M -599M -1.13B
Comprehensive income to owners (USD) -41.8M -47.6M -108M -188M -250M -434M -599M -1.13B
Reported Mar 2, 2021 Feb 28, 2022 Feb 28, 2022 Feb 28, 2022 Feb 27, 2023 Feb 26, 2024 Feb 26, 2025 Feb 25, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

·Received U.S. FDA approval and launched RASONQUE® (daraxonrasib) for adult patients with metastatic pancreatic cancer who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy

·Reported RASONQUE net product revenue of $198 million for the quarter, reflecting a partial quarter of sales following its U.S. commercial launch

·Received positive CHMP opinion recommending marketing authorization of daraxonrasib in the European Union for metastatic pancreatic cancer

·Revolution Medicines to hold webcast today at 4:30 p.m. Eastern Time

REDWOOD CITY, Calif., November 4, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced its financial results for the quarter ended September 30, 2026, and provided an update on corporate progress.

“The U.S.

Prompts

Revolution Medicines, Inc. (ticker RVMD), listed in United States.

ETFs Holding Revolution Medicines, Inc.

ETF Weight in ETF Shares Market value As of
CANC 6.02% 61,768 $ 12.698M Aug 31, 2026
HRTS 3.68% 9,951 $ 2.046M Aug 31, 2026
JXX 2.99% 4,256 $ 798.128K Jul 31, 2026
FMED 2.87% 7,200 $ 1.48M Aug 31, 2026
MEDI 2.70% 6,739 $ 1.188M Nov 12, 2026
DRKY 2.42% 2,536 $ 423.182K Nov 17, 2026
DUNK 2.22% 22,006 $ 3.672M Nov 17, 2026
TAX 1.95% 2,414 $ 496.246K Aug 31, 2026
QMOM 1.77% 41,374 $ 6.73M Nov 18, 2026
MID 1.58% 8,044 $ 1.654M Aug 31, 2026
SSMG 1.29% 220 $ 41.257K Jul 31, 2026
CGMM 1.01% 218,478 $ 36.457M Nov 16, 2026
FRTY 1.00% 8,216 $ 1.539M Jun 30, 2026
FFF 0.78% 241 $ 49.468K Sep 30, 2026
JDOC 0.77% 469 $ 76.302K Nov 17, 2026
TMSL 0.52% 74,976 $ 14.042M Jun 30, 2026
ESSC 0.49% 932 $ 174.778K Jul 31, 2026
ORR 0.41% 9,294 $ 1.51M Nov 18, 2026
SCDS 0.35% 198 $ 32.213K Nov 17, 2026
VFMO 0.32% 30,210 $ 6.21M Aug 31, 2026
VFMV 0.31% 6,754 $ 1.388M Aug 31, 2026
AIVL 0.29% 6,508 $ 1.219M Jun 30, 2026
AVIE 0.27% 271 $ 45.222K Nov 16, 2026
REMC 0.25% 45 $ 8,427.60 Jun 30, 2026
JGRO 0.23% 127,848 $ 20.8M Nov 17, 2026
MODL 0.21% 11,613 $ 2.175M Jun 30, 2026
ESUM 0.18% 1,783 $ 334.366K Jul 31, 2026
FTLS 0.17% 26,668 $ 0.00 Nov 16, 2026
FFLG 0.16% 5,190 $ 973.281K Jul 31, 2026
FEMV 0.16% 45 $ 8,427.60 Jun 30, 2026
FMDE 0.13% 52,711 $ 9.872M Jun 30, 2026
DFAC 0.07% 368,135 $ 64.921M Nov 12, 2026
BDVL 0.07% 6,975 $ 1.164M Nov 16, 2026
FBCG 0.07% 24,808 $ 4.652M Jul 31, 2026
XMAG 0.06% 743 $ 131.028K Nov 13, 2026
JSTC 0.06% 1,106 $ 184.558K Nov 17, 2026
DYNF 0.05% 120,339 $ 20.081M Nov 16, 2026
DFUS 0.05% 55,285 $ 9.75M Nov 12, 2026
TACU 0.04% 47 $ 7,842.89 Nov 17, 2026
DFAU 0.04% 29,859 $ 5.266M Nov 12, 2026
ENHU 0.04% 25 $ 4,171.75 Nov 16, 2026
AVLC 0.04% 3,505 $ 584.879K Nov 16, 2026
MSLC 0.03% 6,637 $ 1.364M Aug 31, 2026
MSSM 0.03% 1,096 $ 225.305K Aug 31, 2026
LCTU 0.03% 2,012 $ 335.742K Nov 16, 2026
DCOR 0.02% 62,781 $ 11.071M Nov 12, 2026
IALT 0.02% 11,769 $ 1.964M Nov 16, 2026
DFSU 0.01% 915 $ 161.36K Nov 12, 2026
DFUV 0.00% 229 $ 40.384K Nov 12, 2026
AVUS 0.00% 1,587 $ 264.823K Nov 16, 2026
NTRL short 0.00% -786 $ 0.00 Nov 16, 2026

Securities

Ticker Type Class Market Exchange Last price Price date
RVMD canonical Common share — US nasdaq 169.09 USD 2026-11-16
RVMDW Warrant — US nasdaq 11.44 USD 2026-09-30